Other Routine +

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

Cardiol Therapeutics Expands Pivotal Trial Network as Enrollment Hits 75%

By The Northwire Desk — AI Analysis Apr 28, 2026 · 07:27 CRDL · 1.91 CARDIOL THERAPEUTICS INC. CL 'A'

Executive Summary

The most recent release (April 28, 2026) confirms expansion of the U.S. MAVERIC Phase III trial network by up to seven additional clinical centers, bringing the total anticipated sites to 25.
Patient enrollment for the MAVERIC study has reached 75%, surpassing the 50% milestone achieved in early January 2026.
The company targets full recruitment by the end of Q2 2026, with potential extension into Q3 2026 to accommodate new sites.
Participating institutions include premier cardiovascular research centers such as Cleveland Clinic, Mayo Clinic, and Massachusetts General Hospital.
Trial design remains randomized, double-blind, placebo-controlled for approximately 110 patients in recurrent pericarditis.
Regulatory context confirms alignment with U.S. FDA end-of-Phase II meeting (April 2025) to support a New Drug Application (NDA).

Material Impact

The news is consistent with the April 1, 2026 update which already reported >50% enrollment and Q2 completion targets; therefore, it lacks genuine surprise elements required for a "Material - Positive" rating.
Progression from 50% (Jan) to 75% (April) indicates strong execution confidence but does not alter the fundamental risk profile of Phase III clinical failure.
Expansion of sites addresses potential recruitment bottlenecks, reducing operational risk rather than creating new value drivers.
No new financing or top-line data is announced; thus, immediate market-moving catalysts are limited to continued trial progress monitoring.
The update validates management's timeline but does not constitute a game-changing event regarding commercialization or regulatory approval status.

CRDL · Price

Company Overview

Cardiol Therapeutics is a clinical-stage biopharmaceutical company focused on inflammatory heart diseases.
Flagship Project: CardiolRx™ (Cannabidiol-based therapy) for recurrent pericarditis under the MAVERIC Phase III trial.
Secondary Program: CRD-38, a subcutaneous formulation targeting inflammatory heart disease including heart failure.
Regulatory Status: U.S. FDA Orphan Drug Designation granted for recurrent pericarditis; U.S. Patent Allowance extending to October 2040.
Phase II ARCHER trial in acute myocarditis showed statistically significant reduction in left ventricular mass (-9.2g, p=0.0117).

More from CARDIOL THERAPEUTICS INC. CL 'A'